Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Shanghai Mental Health Center (Shanghai Psychological Counselling Training Center) is managing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The company's current prosecution is handled by 1 distinct examiner, concentrating the legal focus on a concentrated point of review. This suggests a highly specific technological claim set that does not span different disciplines within the biotechnology field.
The active matter is located within 1 distinct art unit. KATAKAM, SUDHAKAR is the busiest examiner for this portfolio, with 1 busiest examiner pending action. This 1 busiest examiner pending action accounts for the entirety of the center's current activity before the patent office. The prosecution strategy must therefore be tailored to the specific requirements of this 1 art unit and the individual examiner's historical approach to pharmaceutical and psychological health innovations.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WEIDNER, ADAM M | 1 | 63.5% | +33.8% |
| KATAKAM, SUDHAKAR | 1 | 74.7% | +23.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18279961 | APPLICATION OF INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN 2 IN PREPARATION OF DRUGS FOR RESISTING MENTAL DISORDERS CAUSED BY EARLY LIFE STRESS | KATAKAM, SUDHAKAR | 23d overdue |
| 18579591 | USE OF INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2 IN THE PREPARATION OF DRUGS FOR THE TREATMENT OF NEUROLOGICAL DEMYELINATING DISEASES | WEIDNER, ADAM M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18279961 | APPLICATION OF INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN 2 IN PREPARATION OF DRUGS FOR RESISTING MENTAL DISORDERS CAUSED BY EARLY LIFE STRESS | KATAKAM, SUDHAKAR | 23d overdue |
| 18579591 | USE OF INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2 IN THE PREPARATION OF DRUGS FOR THE TREATMENT OF NEUROLOGICAL DEMYELINATING DISEASES | WEIDNER, ADAM M | — |
| Art Unit | Apps |
|---|---|
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18579591 | USE OF INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2 IN THE PREPARATION OF DRUGS FOR THE TREATMENT OF NEUROLOGICAL DEMYELINATING DISEASES | WEIDNER, ADAM M | — | §101§102§112DP | Non-Final OA | — | Pending | Jan 16, 2024 |
| 18279961 | APPLICATION OF INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN 2 IN PREPARATION OF DRUGS FOR RESISTING MENTAL DISORDERS CAUSED BY EARLY LIFE STRESS | KATAKAM, SUDHAKAR | 1658 | §101§102Other | Non-Final OA | 23d overdue | Pending | Sep 01, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial